US4238481A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel cyclopeptides
Assignee: Novartis Corp
•
Filing: 1978-09-15
•
Granted: 1980-12-09
•
Expires: 1998-09-15
Abstract
Abstract Sulphur-free cyclopeptides with somatostatin-analogous aminoacid partial sequences, of the formula <IMAGE> (I) in which R is Asn, Ala or de-R, trp is D-Trp or L-Trp, which can be substituted in the benzene ring by halogen atoms or nitro groups, W is a free or etherified hydroxyl group or halogen atom present as a substituent on the benzene ring of the L-phenylalanine radical, or is hydrogen, X is the radical of an omega -amino-lower alkane-(mono or di)-carboxylic acid or de-X and Y is the radical of an omega -amino-lower alkane-(mono or di)-carboxylic acid or de-Y, and also acid addition salts and complexes thereof have biological properties similar to those of somatostatin and can be used, especially in the form of pharmaceutical preparations, for the treatment of excessive secretion of somatotropin, insulin and/or glucagon. The compounds according to the invention are obtained by cyclising a corresponding linear peptide compound in which the epsilon -amino group of the lysine radical and, if desired, also the hydroxyl group of the threonine radical are protected and detaching the protective groups which are present.
Inventors
- 👤 Hans Rink
- 👤 Bruno Kamber
- 👤 Peter Sieber
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 21:17
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/08; C07K5/0821; A; A61; A61P; A61P43/00; A61P5/00; A61P5/02; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A61K; A61K38/00; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/16
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
109 words
A cyclopeptide of the formula ##STR56## in which R is Asn, trp is D-Trp or L-Trp, which can be substituted in the benzene ring by halogen atoms or nitro groups, W is a free or etherified hydroxyl group or halogen atom present as a substituent on the benzene ring of the L-phenylalanine radical, or is hydrogen, X is the radical of an ω-amino-lower alkane-(mono or di)-carboxylic acid of the formula ##STR57## respectively in which n is an integer from 1 to 7 or de-X and Y is the radical of an ω-amino-lower alkane-(mono or di)-carboxylic acid as defined above or de-Y, or an acid addition salt or complex thereof.
Claim 2
Dependent Claim
109 words
A cyclopeptide of the formula ##STR56## in which R is Asn, trp is D-Trp or L-Trp, which can be substituted in the benzene ring by halogen atoms or nitro groups, W is a free or etherified hydroxyl group or halogen atom present as a substituent on the benzene ring of the L-phenylalanine radical, or is hydrogen, X is the radical of an ω-amino-lower alkane-(mono or di)-carboxylic acid of the formula ##STR57## respectively in which n is an integer from 1 to 7 or de-X and Y is the radical of an ω-amino-lower alkane-(mono or di)-carboxylic acid as defined above or de-Y, or an acid addition salt or complex thereof.
Claim 3
Dependent Claim
73 words
The compound according to claim 1 of the formula I, in which R is Asn, trp is D-Trp or L-Trp, W is hydrogen, X is the radical of an ω-amino-lower alkane-mono-carboxylic acid of the formula --NH--(CH.sub.2).sub.n --CO-- in which n is an integer from 2 to 4, or de-X and Y is the radical of an ω-amino-lower alkane-monocarboxylic acid as defined above or de-Y, or an acid addition salt or a complex thereof.
Claim 4
Dependent Claim
33 words
A compound according to claim 2, in which R is Asn, the tryptophan 8 radical has the D-configuration and --X--Y-- together are --[Gaba] p --, in which p is 0, 1 or 2.
Claim 5
Dependent Claim
209 words
A compound selected from the group consisting of a cyclic peptide of the formula ##STR58## in which R is Asn, trp is D-Trp or L-Trp, which can be substituted in the benzene ring by halogen atoms or nitro groups, W is a free or etherified hydroxyl group or halogen atom present as a substituent on the benzene ring of the L-phenylalanine radical, or is hydrogen, X is the radical of an ω-amino-lower alkane-(mono or di)-carboxylic acid of the formula ##STR59## respectively in which n is an integer from 1 to 7 or de-X and Y is the radical of an ω-amino-lower alkane-(mono or di)-carboxylic acid or as defined above de-Y, A is an ε-amino protective group or hydrogen and B is a hydroxyl protective group or hydrogen, it being possible for only one of the symbols A and B to be hydrogen, and a corresponding linear piptide of the formula H--[II']--C (III) in which II' is a radical corresponding to the formula II characterised above, in which the amide bond between any two adjacent aminoacid radicals of the peptide ring is interrupted, and C is a free hydroxyl group, a hydroxyl group modified by an activating group or the hydrazine group --NH--NH 2 , and acid addition salts thereof.
Claim 6
Dependent Claim
209 words
A compound selected from the group consisting of a cyclic peptide of the formula ##STR58## in which R is Asn, trp is D-Trp or L-Trp, which can be substituted in the benzene ring by halogen atoms or nitro groups, W is a free or etherified hydroxyl group or halogen atom present as a substituent on the benzene ring of the L-phenylalanine radical, or is hydrogen, X is the radical of an ω-amino-lower alkane-(mono or di)-carboxylic acid of the formula ##STR59## respectively in which n is an integer from 1 to 7 or de-X and Y is the radical of an ω-amino-lower alkane-(mono or di)-carboxylic acid or as defined above de-Y, A is an ε-amino protective group or hydrogen and B is a hydroxyl protective group or hydrogen, it being possible for only one of the symbols A and B to be hydrogen, and a corresponding linear piptide of the formula H--[II']--C (III) in which II' is a radical corresponding to the formula II characterised above, in which the amide bond between any two adjacent aminoacid radicals of the peptide ring is interrupted, and C is a free hydroxyl group, a hydroxyl group modified by an activating group or the hydrazine group --NH--NH 2 , and acid addition salts thereof.
Claim 7
Dependent Claim
88 words
A linear peptide according to claim 4, of the formula H-R-Phe-Phe-trp-Lys(A)-Thr(B)-Phe-X-Y-C (IIIc) in which R is Asn, trp is D-Trp or L-Trp, X is the radical of an ω-amino-lower alkane-monocarboxylic acid of the formula --NH--(CH.sub.2).sub.n --CO-- in which n is an integer from 1 to 7, or de-X and Y is the radical of an ω-amino-lower alkane-monocarboxylic acid as defined above or de-Y, A is an ε-amino protective group, B is a hydroxyl protective group and C is a free carboxyl group, or an acid addition salt thereof.
Claim 8
Dependent Claim
7 words
A compound characterised by the formula ##STR60##
Claim 9
Dependent Claim
7 words
A compound characterised by the formula ##STR60##
Claim 10
Dependent Claim
7 words
A compound characterised by the formula ##STR61##
Claim 11
Dependent Claim
7 words
A compound characterised by the formula ##STR61##
Claim 12
Dependent Claim
26 words
A compound characterised by the formula ##STR62## in which A is the tert.-butoxycarbonyl group and B is the tert.-butyl group and p is 1 or 2.
Claim 13
Dependent Claim
26 words
A compound characterised by the formula ##STR62## in which A is the tert.-butoxycarbonyl group and B is the tert.-butyl group and p is 1 or 2.
Claim 14
Dependent Claim
50 words
A pharmaceutical preparation for the treatment of excessive secretion of somatotrophin insulin and/or glucagon which contains an effective amount of at least one of the compounds characterised in any one of claims 3-9, 2 or 1 in combination or admixture with at least one inert, physiologically tolerable carrier and/or adjunct.
Claim 15
Independent Claim
33 words
A method for the therapeutic treatment of excessive secretion of somatotropin, insulin and/or glucagon by administering a therapeutically effective dose of a compound characterised in any one of claims 3-7, 2 or 1.
References Cited (Backward Citations)
NL7602793A
Cited
US4000259A
Cited
DE2635558A1
Cited
US3988304A
Cited
US4054558A
Cited
US4146612A
Cited
US4115554A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-12-09 | 1984-06-09 | 1984-12-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-12-09 | 1988-06-09 | 1988-12-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-12-09 | 1992-06-09 | 1992-12-09 | $7700.00 | Window Closed / Lapsed |